Lilly reports positive clinical urothelial carcinoma data for Cyramza

Lilly has announced new clinical data that highlights the progression-free survival benefits that Cyramza can provide in the treatment of urothelial carcinoma.

Data from the phase III RANGE study have been presented at the 2017 European Society for Medical Oncology 2017 Congress showing the benefits offered by Cyramza in combination with docetaxel among patients with advanced or metastatic urothelial carcinoma whose disease had progressed on or after platinum-based chemotherapy.

A statistically significant 46 percent improvement in progression-free survival rates was observed among Cyramza recipients when compared to those who received placebo plus docetaxel.

This represents the first phase III study of any therapy to show superior progression-free survival compared to chemotherapy in a post-platinum setting in urothelial cancer, while the drug is also the first anti-angiogenic agent to extend survival in this setting.

Dr Levi Garraway, senior vice-president for global development and medical affairs at Lilly Oncology, said: "The RANGE data provides additional evidence in favour of combining Cyramza with other therapeutic backbones, which has now demonstrated an efficacy improvement in treating several types of aggressive metastatic cancers."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.